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Summary
Objective: One of the proteoglycan families is the small leucine-rich proteoglycans (SLRPs) that are characterized by their association with
collagen ﬁbrils and/or some glycosaminoglycans. Opticin is a glycoprotein and class III member of the SLRP family, which was initially iden-
tiﬁed in the vitreous humour of the eye. In this study, we ﬁrst investigated whether opticin is expressed and produced in normal and OA human
articular tissues/cells. Further, we investigated the ability of the key metalloprotease involved in cartilage pathology, MMP-13, to cleave human
cartilage opticin.
Methods: Opticin gene expression was investigated in normal and OA human chondrocytes, synovial ﬁbroblasts, and subchondral bone
osteoblasts by reverse transcriptase-polymerase chain reaction (RT-PCR). Opticin protein production was determined in normal and OA
synovial membrane and cartilage by immunohistochemistry. Opticin was isolated from human cartilage using guanidinium chloride extraction,
and human MMP-13-induced opticin degradation analyzed by Western blotting. Finally, the opticin MMP-13 cleavage site was determined.
Results: Opticin was expressed in human chondrocytes, synovial ﬁbroblasts and subchondral osteoblasts, and the protein identiﬁed in syno-
vial membrane and cartilage. At the protein level, OA cartilage showed a slightly higher level of opticin positive stained chondrocytes than
normal cartilage; this did not reach statistical signiﬁcance. However, in contrast with OA, normal cartilage demonstrated a high level of matrix
staining in the superﬁcial zone of the tissue, suggesting that in the OA cartilage matrix, opticin is degraded. Data also showed that cartilage
opticin could be cleaved by MMP-13 after only 2 h of incubation, indicating a preferential substrate compared to other SLRPs for this enzyme.
Microsequencing revealed a major cleavage site at the G104/L105LAAP and a minor at P109/A110NHPG upon MMP-13 exposure.
Conclusion: We demonstrated, for the ﬁrst time, that opticin is expressed and produced in human articular tissues. Our data also showed that
opticin in OA cartilage is degraded in a process that could be mediated by MMP-13. As opticin may contribute towards the structural stability of
cartilage, its cleavage by MMP-13 may predispose cartilage to degeneration, particularly at the surface.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most prevalent form of rheumato-
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749of men and 18% of women and about 60e65% aged over
60 years have symptomatic osteoarthritis, and 80% of those
have limitations in movement. OA is characterized mainly
by the degradation of articular cartilage with an imbalance
between anabolic and catabolic pathways in which an in-
crease in the proteolysis of aggrecan (proteoglycan) and
collagen is prominent2.
Proteoglycans form a large group that includes the small
leucine-rich proteoglycans (SLRPs). The SLRP family,
which is now thought to consist of 12 members3, is charac-
terized by a protein core containing tandem leucine-rich re-
peats (LRRs) ﬂanked by conserved cysteine residues4.
750 J. Monfort et al.: Opticin a target for MMP-13 in osteoarthritisSLRPs also possess a variable amino-terminal extension to
the LRR-containing region. Eleven of the 12 members of
this family are divided into three classes based on their ge-
nomic organization, the number of LRR, and the consensus
sequence of a cysteine cluster at the N-terminal end of the
LRR domain3e5: class I includes decorin, biglycan and as-
porin; class II includes ﬁbromodulin, lumican, keratocan,
PRELP and osteoadherin; and class III includes epiphycan,
mimecan and opticin. Their importance in extracellular
matrix organization5 was highlighted by the phenotype of
some SLRP knock-out mice including decorin-null6, lumi-
can-null7 and ﬁbromodulin-null8, which showed abnormal
collagen ﬁbrils with uneven diameter and irregular structure,
suggesting that their presence is essential for normal ﬁbril
(and hence tissue) morphology.
Opticin (also knownasoculoglycan;MIM*605127), amem-
ber of the third SLRP class, is an extracellular matrix glyco-
protein that was ﬁrst identiﬁed by Reardon et al.9 and found
associated with the collagen ﬁbrils of the vitreous humour of
the eye. Opticin mRNA has been detected in the non-pig-
mented ciliary epithelium of the eye10e12 and a variety of
non-ocular tissues including cartilage, brain, ligament, liver,
testis,muscleandskin9,13,14.Opticin is adimeric glycoprotein
with each monomer being composed of eight LRRs15. While
SLRPsare generally proteoglycans, opticin is an exception in
that instead of possessing glycosaminoglycan side chain(s),
it is a glycoprotein with an amino-terminal region containing
a cluster of serine and threonine residues that are heavily
substituted with sialylated O-linked oligosaccharides9,15.
Several SLRPs, including opticin, bind noncovalently to
collagen ﬁbrils and opticin may play a role in maintaining ﬁ-
bril spacing16. Recent studies have shown that opticin binds
to glycosaminoglycans, including heparan sulfate and chon-
droitin sulfate17 which are essential in cartilage structure and
maintenance18, and that other putative functions include the
inhibition of angiogenesis and growth hormone binding19,20.
Extracellular matrix turnover is an integral part of develop-
ment, morphogenesis and tissue remodeling. While various
types of proteases participate in matrix turnover, the matrix
metalloproteases (MMPs) are the major matrix-degrading
proteases in OA cartilage, and MMP-13 (collagenase-3)
was found to be highly involved in this diseased tissue21.
In addition to degrading type IeIII collagens, MMP-13 has
a telopeptidase activity and the ability to degrade a number
of other components of the extracellular matrix including ﬁ-
bronectin, ﬁbrillin, types IV, IX, X and XIV collagens, gelatin,
galectin-3, and aggrecan [see review,22]. Recently, MMP-13
has demonstrated its ability to cleave some of the SLRPs,
including biglycan, decorin, ﬁbromodulin and lumican23e26.
In the present study, we ﬁrst investigated the production
of opticin in human articular tissues/cells and then evalu-
ated the effect of MMP-13 on opticin in human OA cartilage.
Data showed, for the ﬁrst time, that opticin is expressed and
produced by human chondrocytes, synovial ﬁbroblasts and
subchondral bone osteoblasts. Moreover, MMP-13 is able
to cleave opticin, which may result in its functional failure,
thereby resulting in loss of matrix structure and function.Materials and methodsSPECIMEN SELECTIONNormal human knee cartilage and synovial membranes were obtained
within 12 h of death from individuals (mean age SD, 66 5 years) who
had no history of joint disease or metabolic bone disease and died of causes
unrelated to arthritic diseases. The tissues were examined macroscopically
and microscopically to ensure that only normal tissue was used. Individuals
showing cartilage deterioration were not included in the normal group.Human OA specimens were obtained from patients undergoing total knee
arthroplasty (mean ageSD, 71 9). All patients were evaluated as having
OA according to recognized American College of Rheumatology Clinical Cri-
teria27. At the time of surgery the patients had symptomatic disease requiring
medical treatment in the form of acetaminophen, nonsteroidal anti-inﬂamma-
tory drugs (NSAIDs), or selective cyclooxygenase-2 inhibitors. None had re-
ceived intra-articular steroid injections within 3 months prior to surgery, and
none had received medication that would interfere with bone metabolism.
The Institutional Research Ethics Committee of the University of Montreal
Hospital Centre approved the use of the human articular tissues.PROTEOGLYCAN EXTRACTIONProteoglycans were extracted with guanidinium chloride, as previously
described26,28. Brieﬂy, cartilage was ﬁnely diced and extracted with 4 mol/L
guanidinium chloride (Invitrogen Inc., Carlsbad, CA, USA) in 0.1 mol/L so-
dium acetate (pH 6.0) containing protease inhibitors (leupeptin [10 mg/mL],
pepstatin [10 mg/mL], aprotinin [10 mg/mL], 1,10-phenanthroline [10 mg/mL]
and phenylmethanesulphonyl ﬂuoride [100 mg/mL]) (EMD Biosciences Inc.,
La Jolla, CA, USA) at 4C with continuous stirring for 48 h. The extract
was then separated from the cartilage residue by ﬁltration through glass
wool, and then dialysed for 48 h against 50 mmol/L Tris buffer (pH 7.5).OPTICIN mRNA DETECTIONChondrocytes and synovial ﬁbroblasts were released from full-thickness
strips of articular cartilage and synovial membrane, respectively, by sequen-
tial enzymatic digestion at 37C, as previously described29. The cells were
seeded at high density (105 cells/cm2) in tissue culture ﬂasks and cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM; GibcoeBRL, Burlington,
ON, Canada) supplemented with 10% heat-inactivated fetal calf serum
(FCS; GibcoeBRL) and an antibiotic mixture (100 units/mL penicillin base
and 100 mg/mL streptomycin base; GibcoeBRL) at 37C in a humidiﬁed at-
mosphere of 5% CO2/95% air. Cells were maintained in culture for 5e7
days. Primary cell cultures were used. Subchondral bone osteoblast release
was as previously described30. In brief, the overlying cartilage was removed
and the trabecular bone tissue dissected from the subchondral bone plate. All
manipulations were performed under a magnifying microscope to ensure the
complete removal of cartilage and trabecular bone. Bone samples were cut
into small pieces prior to sequential digestion in the presence of collagenase
type I in BGJb medium without serum at 37C in a humidiﬁed atmosphere. Af-
ter a 4-h incubation period the bone pieces were cultured in BGJb medium
containing 20% FCS and the antibiotic mixture at 37C. This medium was re-
placed every 2 days until cells were observed in the petri dishes. At this point,
the culture medium was replaced with fresh medium containing 10% FCS un-
til conﬂuence. Osteoblasts passaged once were used.
Total cellular RNA from cells was extracted with the TRIzol reagent
(Invitrogen) according to the manufacturer’s speciﬁcations and treated with
the DNA-free DNase Treatment and Removal kit (Ambion, Austin, TX,
USA) to ensure the complete removal of chromosomal DNA. The RT reac-
tions were primed with random hexamers as described previously31, with
2 mg of total RNA in a 20 ml ﬁnal reaction volume. The polymerase chain re-
action (PCR) was carried out for 40 cycles of 94C for 1 min and an anneal-
ing/extension step at 60C for 1 min and 30 s. Primers were derived from the
published sequence of the opticin gene (access #NM014359). The primers
50-TTGACCTCTCCAACAACCTC-30 (forward) and 50-GGTCACAGAAGACG
TCTCTC-30 (reverse) ampliﬁed a single 327 bp fragment. The identity of the
ampliﬁed fragment was tested by (1) restriction with Pst1, which speciﬁcally
cleaves the fragment, and (2) by DNA sequencing.OPTICIN CLEAVAGES BY MMP-13MMP-13 proteolytic activity was analyzed on proteoglycan extracts from
normal and OA human cartilage having different levels of ﬁbrillation corre-
sponding to different stages of the disease process. These were named
slightly, moderately and severely ﬁbrillated cartilage. These extracts were in-
cubated for 0e16 h with human recombinant (rh)MMP-13 (R&D Systems
Inc., Minneapolis, MN, USA) activated with 0.5 mmol/L aminophenylmercuric
acetate (APMA; Kodak Inc., Toronto, ON, Canada) in 50 mmol/L TriseHCl
(pH 7.5) containing 10 mmol/L CaCl2 and 0.05% Brij 35 (SigmaeAldrich
Canada Ltd., Oakville, ON, Canada) at an MMP-13/proteoglycan ratio of
1:50 (100 ng/5 mg). Glycosaminoglycan content was determined by the
DMMB method32. The reaction was stopped by the addition of EDTA
(SigmaeAldrich Canada Ltd.) at a ﬁnal concentration of 15 mM.WESTERN BLOTTINGMMP-13 treated and non-treated proteoglycan extracts were mixed with
a sample buffer (62.5 mmol/L TriseHCl [pH 6.8], 2% w/v sodium dodecyl sul-
phate, 10% glycerol, 5% b-mercaptoethanol and 0.05% bromophenol blue)
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751Osteoarthritis and Cartilage Vol. 16, No. 7and electrophoresed on 4e20% Ready-Gels (Bio-Rad Laboratories Ltd.,
Mississauga, ON, Canada). The proteoglycan extracts were then transferred
electrophoretically onto nitrocellulose membranes (Bio-Rad Laboratories
Ltd.) and processed for Western immunoblotting. Blots were blocked in 5%
low fat dry milk in Tris-buffered saline containing 0.05% Tween 20
(SigmaeAldrich Canada Ltd.). The primary antibody was a polyclonal rabbit
that recognizes the N-terminus of the human opticin core protein as de-
scribed previously11. For Western blotting a 1/10,000 dilution was used.
The secondary antibody was a horseradish peroxidase-conjugated goat
anti-rabbit immunoglobulin (1/10,000 dilution; Pierce, Rockford, IL, USA).
For comparison purposes, another antibody was also used: a polyclonal
goat anti-human opticin (#AF3148; R&D Systems, Minneapolis, MN, USA)
at a 1/2000 dilution. The secondary antibody was a mouse anti-goat immu-
noglobulin (1/10,000 dilution; Pierce). Detection was performed by chemilu-
minescence using the Super Signal West Dura Extended Duration
substrate (Pierce), in accordance with the manufacturer’s speciﬁcations.400
300IMMUNOHISTOCHEMISTRY
200
100
Fig. 1. Representative PCR blot of the expression of opticin in
human OA articular chondrocytes (C), synovial ﬁbroblasts (S) and
osteoblasts from subchondral bone (OB). The restriction enzyme
Pst1 was used to conﬁrm the speciﬁcity of the PCR primer. kDa in-
dicates the PCR markers’ molecular weight, and M, marker.Cartilage and synovial membrane specimens were processed for immu-
nohistochemistry as previously described33. The specimens were ﬁxed in
4% paraformaldehyde and embedded in parafﬁn. Sections (5 mm) of
parafﬁn-embedded specimens were deparafﬁnized in toluene and rehy-
drated in a graded series of ethanol. The cartilage specimens were then
pre-incubated with chondroitinase ABC (0.25 units/mL in PBS [pH 8.0]) for
60 min at 37C, and both cartilage and synovial membrane with Triton X-
100 (0.3%) for 30 min at room temperature. Slides were then washed in
PBS followed by 0.3% hydrogen peroxide/methanol for 30 min. They were
further incubated for 60 min with 2% normal serum (Vector Laboratories, Bur-
lingame, CA, USA) and overlaid with the rabbit anti-human opticin antibody
(1/1000 dilution) for 18 h at 4C in a humidiﬁed chamber. The second anti-
body was a goat anti-rabbit immunoglobulin (Vector Laboratories).
Each slide was washed three times in PBS (pH 7.4) and stained using the
avidinebiotin complex method (Vectastain ABC kit; Vector Laboratories).
The color was developed with 3,30-diaminobenzidine (Vector Laboratories)
containing hydrogen peroxide. The slides were counter-stained with eosin.
Controls were done to determine the speciﬁcity of staining: (1) substitution
of the primary antibodies with non-speciﬁc rabbit IgG (Chemicon Interna-
tional, Temecula, CA, USA) used at the same concentration as the primary
antibody; (2) immunoadsorbed with 25-fold excess of the recombinant opti-
cin; and (3) omission of primary antibody. Controls showed only background
staining.
The total number of chondrocytes and the total number of positively
stained chondrocytes were counted as previously described33. As no chon-
drocytes staining positive were found in the deep zone (lower intermediate
and deep layers), the ﬁnal results were expressed as the percentage of pos-
itive chondrocytes of the superﬁcial zone (superﬁcial and upper intermediate
layers). Brieﬂy, for each cartilage specimen, the total number of chondro-
cytes and the total number of positive chondrocytes were counted sepa-
rately, at 40 magniﬁcation, from three ﬁelds of the superﬁcial zone. Each
slide was subjected to a double-blind evaluation with a variation of <5%.PROTEIN SEQUENCING OF MMP-13 OPTICIN CLEAVAGE
PRODUCTBovine recombinant opticin15 was incubated with APMA-activated
rhMMP-13 in 50 mmol/L TriseHCl (pH 7.5), containing 10 nmol/L CaCl2
and 0.05% Brij 35, for 8 h at 37C. The reaction was stopped by the addition
of EDTA at a ﬁnal concentration of 15 mM. Degradation products were
separated in 4e20% polyacrylamide gels (Bio-Rad Laboratories Ltd.). After
electrophoresis, the gels were soaked in CAPS transfer buffer (10 nmol/L
3-cyclohexylamino-1-propanesulfonic acid, 10% methanol [pH 11.0]) for
15 min at 0.25 A. After washing, the protein was transferred onto PVDF
membranes (Millipore Corporation, Bedford, MA, USA), which were washed
in deionized water, stained with 0.1% Coomassie Blue in 50% methanol for
5 min, and then destained in 50% methanol and 10% acetic acid for 5e7 min
at room temperature. Finally, the membrane was rinsed in deionized water,
air dried and stored at room temperature. Amino-terminal amino acid se-
quencing of the protein band was performed on a Procise Protein Sequencer
model 492 (Applied Biosystems, Foster City, CA, USA).ResultsOPTICIN EXPRESSION BY HUMAN OA ARTICULAR CELLSAs represented in Fig. 1, opticin is expressed in human
OA chondrocytes (n¼ 3), synovial ﬁbroblasts (n¼ 3) and
subchondral bone osteoblasts (n¼ 3). In order to conﬁrm
the speciﬁcity of the band, they were treated with theenzyme Pst1, and data indicate that the enzyme speciﬁcally
cleaves the fragment (Fig. 1). Further DNA sequencing
conﬁrmed that the ampliﬁcated fragment of the reverse
transcriptase-PCR (RT-PCR) corresponded to human opticin.
Further data showed that opticin is produced in both nor-
mal (n¼ 2) and OA (n¼ 4) human synovial membranes and
cartilages (normal, n¼ 6; OA, n¼ 6) [Fig. 2(A and B)]. In
both normal and OA synovial membranes, opticin is pro-
duced in the synovial lining cells and in the endothelial cells
of the vessel wall, as well as in cell inﬁltration in OA
[Fig. 2(A)]. Of note, although opticin is found in the same
cells when OA and normal tissues are compared, there
are, in the OA synovial membrane, more layers of the lining
cells as well as cell inﬁltration, thus more cells producing
opticin.
In cartilage [Fig. 2(B)], chondrocytes producing opticin
are found mostly in the superﬁcial layers of the tissue for
both cartilage types. Analysis of opticin positive chondro-
cytes at this level showed that although a higher level of
positive chondrocytes was found in OA samples, this did
not reach statistical signiﬁcance [Fig. 2(C)]. Interestingly,
matrix opticin speciﬁc staining was present in normal carti-
lage, but had almost disappeared in OA cartilage [Fig. 2(B)].
The disappearance of the matrix staining occurred in all OA
specimens regardless of the severity of the disease (data
not shown).MMP-13-INDUCED OPTICIN DEGRADATIONWestern blotting revealed that the cartilage extracted
human opticin differed in the apparent molecular weight
from the bovine recombinant opticin. As illustrated in
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Fig. 2. Representative opticin immunohistochemical sections of normal and OA human (A) synovial membranes, and (B) cartilage (original
magniﬁcation 250). The red arrows indicate the opticin speciﬁc positive staining. In the synovial membrane (A), opticin is found in the cells
from the lining layer and the endothelial cells, as well as in osteoarthritis in the cell inﬁltration. In cartilage (B), opticin is found in the superﬁcial
zone. Superﬁcial (superﬁcial and upper intermediate layers) and deep (lower intermediate and deep layers) zones of cartilage are indicated
with black arrows. For both synovial membrane and cartilage no speciﬁc staining was detected with the controls including the immuno-
adsorbed with recombinant opticin (data not shown). Of note, in (B) there is extracellular matrix opticin speciﬁc staining in normal cartilage
in the superﬁcial zone, which had almost disappeared in OA cartilage. (C) Analysis of the chondrocyte opticin speciﬁc staining at the super-
ﬁcial zone. Data are expressed as median and range and are presented as box plots, where the boxes represent the ﬁrst and third quartiles,
the line within the box represents the median, and the lines outside the box represent the spread of values. Statistical analysis was done using
Student’s t test comparing normal and OA cartilages; no statistical difference was found.
752 J. Monfort et al.: Opticin a target for MMP-13 in osteoarthritis[Fig. 3(A)], data showed that bovine opticin migrated at an
apparent molecular weight of 40e45 kDa whereas the hu-
man opticin migrates as a doublet of 55e60 kDa. To verify
that the immunoreactivity was not due to the rabbit anti-
human antibody, another antibody, a goat anti-human,
was used and results were similar [Fig. 3(A)]. In any case,
none of the antibodies used recognized a 40e45 kDa
fragment.
Specimens incubated with MMP-13 showed that opticin
degradation was time-dependent and clearly visible after
2 h of incubation, and almost complete at 8 h [Fig. 3(B)].
No true differences in the opticin degradation were ob-
served between the specimens from normal and OA carti-
lages according to the degree of cartilage ﬁbrillation
severity.MMP-13 CLEAVAGE SITE OF OPTICINAmino-terminal amino acid sequencing was performed
on the major opticin fragment of approximately 24 kDa pro-
duced by MMP-13 digestion (Fig. 4). Two sequences were
identiﬁed which corresponded to a major cleavage between
positions G104 and L105LAAP, and a minor one between po-
sitions P109 and A110NHPG of the mature opticin core pro-
tein. Therefore the 24-kDa fragment was composed of theLRR domains with ﬂanking cysteines, but the amino-termi-
nal domain containing the sialylated O-linked oligosaccha-
rides has been removed by MMP-13 digestion.Discussion
The present study showed for the ﬁrst time that opticin is
expressed in human knee tissues including articular carti-
lage, synovial membrane and subchondral bone and the
protein has been identiﬁed in cartilage and synovial mem-
brane. Interestingly, MMP-13 cleavage of opticin in cartilage
occurred early and was extensive, suggesting that this mol-
ecule is a preferential substrate among the SLRPs for this
enzyme. We also characterized the major cleavage site
for opticin and this was located between amino acids G104
and L105. We hypothesize that MMP-13-induced opticin
degradation may represent an early critical event in the pro-
cess of cartilage degradation.
Opticin exists as a noncovalently linked dimer in solution
but runs as a monomer on SDS-PAGE. Recombinant
bovine opticin ran as a diffuse component at approximately
45 kDa. The opticin in the human cartilage extract migrated
somewhat more slowly (approximately 55e60 kDa by SDS-
PAGE). It is assumed that the differences in electrophoretic
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Fig. 3. Representative Western blots of (A) recombinant bovine opticin and human opticin extracts from cartilage, using two different anti-
bodies, illustrating that the human opticin is at a higher apparent molecular weight than the recombinant form. (B) Time course of MMP-
13-induced degradation of opticin. Human cartilage extracts were incubated with APMA-activated MMP-13 for the indicated time (0e16 h).
Panels show Western blots of extracts probed with the rabbit anti-opticin from normal cartilage or from slightly, moderately and severely
ﬁbrillated OA cartilage.
753Osteoarthritis and Cartilage Vol. 16, No. 7migration are due to differences in the extent of O-glycosyl-
ation. Opticin is the only SRLP known to contain a large
cluster of sialylated O-linked oligosaccharides, thereby pro-
viding an alternative form of anionic carbohydrate to the
more usual glycosaminoglycan chains5,9. The functional55
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Fig. 4. Schematic representation of recombinant opticin cleavage site gen
MMP-13-cleavage site in thsigniﬁcance of the sialylated O-linked oligosaccharides on
opticin remains unknown.
OA is a multifactorial disorder involving cartilage, synovial
membrane and subchondral bone34, and in each of these
tissues MMP-13 has been found in increased amountsOpticin
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754 J. Monfort et al.: Opticin a target for MMP-13 in osteoarthritisand appears responsible, at least in part, for the tissue deg-
radation. Although MMP-13 acts on various matrix macro-
molecules, this is the ﬁrst time that its effect was
investigated on a member of the class III SLRPs. Here,
we assessed the degradative effect of MMP-13 on opticin
on normal human cartilage and on three different stages
of OA cartilage. Data showed that MMP-13 cleaves opticin,
and that the degree of degradation was independent of the
cartilage damage severity. MMP-13 has different catalytic
activities including collagenolytic and gelatinolytic, in addi-
tion to showing strong aggrecanase properties35,36. There-
fore, depending on the substrate, it can degrade SLRPs
with its collagenase or gelatinase activity, or with both, re-
sulting in a faster degradation of the substrate26. Our data
suggest that opticin is sensitive to both of the MMP-13 cat-
alytic activities, since, in comparison with the degradation
speed for biglycan and ﬁbromodulin26, the degradation of
the glycoprotein occurs early and is clearly visible after
only 2 h of incubation.
The 24-kDa band obtained in the opticin digestion with
MMP-13 included two fragments: a major one that has
been cleaved between positions G104 and L105LAAP, and
the minor one between positions P109 and A110NHPG. Ef-
forts have been devoted to establish the consensus cleav-
age motif of each MMP. However, a speciﬁc pattern could
not be ascertained as the MMP cleavage sites for the differ-
ent substrates share little sequence homology and lack an
obvious consensus cleavage motif. Here, the fact that
MMP-13 cleaves opticin at two different but close sites with-
out any homology may indicate that the recognition and
cleavage sites are distinct. One possibility is that MMP-13
ﬁrst binds to a region and then cleaves opticin some amino
acids away from this recognition site. A second hypothesis
is that, if collagenolytic and gelatinolytic MMP-13 activities
are working together, each of them could recognize differ-
ent cleavage sites on opticin. Another point of interest is
that a fragment of a similar size is also noted in the control
(untreated recombinant opticin), indicating the occurrence
of such a cleavage in the cell from which the opticin was pu-
riﬁed, hence this MMP-13 activity could have occurred
in vivo. This could very well be the case, as the recombinant
opticin was puriﬁed from human embryonic kidney cells13,
and MMP-13 is active during embryonic development37,38.
It is then possible that the MMP-13 opticin fragment was
also puriﬁed along with the mature opticin, although we can-
not exclude the possibility that other proteases exerted this
effect. However, the fact that it could be seen in an in-
creased intensity of the band after the treatment with the
protease suggests that MMP-13 is related to this digestion.
Of note, is that the 24-kDa fragment could not be de-
tected with the antibodies used in this study. This could
be explained by the fact that the antibodies recognized
the N-terminus of the core protein, and that the fragment
is at the C-terminus region of the opticin.
As MMP-13 has been suggested to be present in carti-
lage during its remodelling39,40, hence at an early stage of
the disease, it is tempting to hypothesize that opticin cleav-
age may represent an early critical event. Opticin may have
a direct involvement in maintaining the spacing of collagen
ﬁbrils and therefore degradation of opticin could cause di-
rect structural damage. Alternatively, the degradation of op-
ticin may affect the collagen network by uncovering the
collagenase cleavage site on this molecule or it could ex-
pose proteoglycans to cleavage since it has been shown
to bind chondroitin sulphate and heparin sulphate17. The
degradation of collagen and/or proteoglycans would lead
to cartilage degeneration. This hypothesis is supported byour data showing the ability of MMP-13 to cleave opticin
in a similar manner in normal and OA cartilages. Moreover,
the ﬁnding that opticin in normal cartilage, in contrast to OA,
had a high level of matrix staining in the superﬁcial zone in-
dicates that in situ in OA cartilage, opticin in the matrix is de-
graded and that the degradation product may not be
retained within the cartilage matrix, hence it does not accu-
mulate. The degradation of opticin by MMP-13 in situ in OA
cartilage is further supported by the fact that this enzyme is
produced at a very low level in normal cartilage29,41,42, and
that in OA, this protease is detected in all cartilage
layers39,40. In addition, the lack of difference in chondro-
cytes producing opticin between normal and OA cartilage
indicates that the production of this SLRP is not modulated
in this tissue by the events occurring during the disease pro-
cess, emphasizing the importance of the degradation of this
molecule during the pathological progression. This could
also apply to the synovial membrane, where there was no
difference in the cell types producing opticin in normal
and OA.
In this study, we examined the effect of MMP-13 on opti-
cin, as this MMP is highly involved in OA pathogenesis.
However, this does not rule out that this SLRP could be de-
graded by other proteases also involved in this disease pro-
cess. In this context, it has recently been shown43 that
a member of the SLRP family, the biglycan, can be cleaved
by the aggrecanases, but not decorin which belongs to the
same SLRP class. More should be known about the con-
sensus sequence recognition of each protease in order to
predict which proteases could interact with each of the
SLRP members.
In summary, opticin is present in human articular tissues
and MMP-13 has the ability to cleave it. The fact that MMP-
13 could cleave numerous cartilage matrix components, in-
cluding type II collagen and members of the SLRPs, that
bind to this collagen, could explain why this collagenase
plays a major role in osteoarthritis.Conﬂict of interest
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